The Journal is included in Russian and International Library and Abstract Databases
Russain Science Index (Russia)
DOI Registration Agency (USA)

What conclusions should be drawn from the association between liver diseases and cholelithiasis?


Yu. Tonkikh, Candidate of Medical Sciences; A. Vasyutin, Candidate of Medical Sciences; Professor V. Tsukanov, MD Research Institute for Medical Problems of the North (Separate Subdivision), Federal Research Center «Krasnoyarsk Research Center, Siberian Branch, Russian Academy of Sciences», Krasnoyarsk

The authors reviewed current data, which could establish a pronounced association between the prevalence of cholelithiasis and liver diseases. A century-and-a-half discussion about the prevalence of the basic concepts of the pathogenesis of cholelithiasis led to the unification of metabolic and infectious theories. Currently, surgical tactics involving cholecystectomy in individuals with symptomatic or complicated cholelithiasis predominates in an approach to treating gallstones. A multidisciplinary view on the diagnosis, pathogenesis, treatment, and prevention of cholelithiasis and the recognition of a close relationship between the functional state and pathology of the liver and biliary tract justifies the feasibility of a thorough diagnosis of pathology of the liver and correction of its functional state in patients with cholelithiasis. Ursodeoxycholic acid is a good example of therapy that improves both the functional state of the liver and that of the biliary tract.

non-alcoholic fatty liver disease
ursodeoxycholic acid

  1. Kim Y.K., Kwon O.S., Her K.H. The grade of nonalcoholic fatty liver disease is an independent risk factor for gallstone disease: An observational Study. Medicine (Baltimore). 2019; 98 (27): e16018. DOI: 10.1097/MD.0000000000016018
  2. Lee Y.C., Wu J.S., Yang Y.C. et al. Moderate to severe, but not mild, nonalcoholic fatty liver disease associated with increased risk of gallstone disease. Scand J Gastroenterol. 2014; 49 (8): 1001–6. DOI: 10.3109/00365521.2014.920912
  3. Jaruvongvanich V., Sanguankeo A., Upala S. et al. Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2016; 61 (8): 2389–96. DOI: 10.1007/s10620-016-4125-2
  4. Kwak M.S., Kim D., Chung G.E. et al. Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. World J Gastroenterol. 2015; 21 (20): 6287–95. DOI: 10.3748/wjg.v21.i20.6287
  5. Ruhl C.E., Everhart J.E. Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population. Am J Gastroenterol. 2013; 108 (6): 952–8. DOI: 10.1038/ajg.2013.70
  6. Benvegnù L., Noventa F., Chemello L. et al. Prevalence and incidence of cholecystolithiasis in cirrhosis and relation to the etiology of liver disease. Digestion. 1997; 58 (3): 293–8. DOI: 10.1159/000201457
  7. Conte D., Fraquelli M., Fornari F. et al. Close relation between cirrhosis and gallstones: cross-sectional and longitudinal survey. Arch Intern Med. 1999; 159 (1): 49–52. DOI: 10.1001/archinte.159.1.49
  8. Buchner A.M., Sonnenberg A. Factors influencing the prevalence of gallstones in liver disease: the beneficial and harmful influences of alcohol. Am J Gastroenterol. 2002; 97 (4): 905–9. DOI: 10.1111/j.1572-0241.2002.05607.x
  9. Acalovschi M., Badea R., Pascu M. Incidence of gallstones in liver cirrhosis // Am. J. Gastroenterol. – 1991; 86 (9): 1179–81.
  10. Del Olmo J.A., Garcia F., Serra M.A. et al. Prevalence and incidence of gallstones in liver cirrhosis. Scand J Gastroenterol. 1997; 32 (10): 1061–5. DOI: 10.3109/00365529709011225
  11. Elzouki A.N., Nilsson S., Nilsson P. et al. The prevalence of gallstones in chronic liver disease is related to degree of liver dysfunction. Hepatogastroenterology. 1999; 46 (29): 2946–50.
  12. Admirand W.H., Small D.M. The physicochemical basis of cholesterol gallstone formation in man. J Clin Invest. 1968; 47 (5): 1043–52. DOI: 10.1172/JCI105794
  13. Carey M.C. Pathogenesis of gallstones. Am J Surg. 1993; 165 (4): 410–9. DOI: 10.1016/s0002-9610(05)80932-8
  14. Tonkih Ju.L., Tsukanov V.V. Helicobacter Pylori i zabolevanija zhelchevyvodjaschih putej: suschestvuet li vzaimosvjaz'? Vrach. 2013; 10: 66–8 [Tonkih J.L, Tsukanov V.V. Association of infectious factors with biliary tract diseases? Vrach. 2013; 10: 66–8 (in Russ.)].
  15. Lammert F., Gurusamy K., Ko C.W. et al. Gallstones. Nat Rev Dis Primers. 2016; 2: 16024. DOI: 10.1038/nrdp.2016.24
  16. Katsika D., Grjibovski A., Einarsson C. et al. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology. 2005; 41 (5): 1138–43. DOI: 10.1002/hep.20654
  17. Nakeeb A., Comuzzie A.G., Martin L. Gallstones: genetics versus environment. Ann Surg. 2002; 235 (6): 842–9. DOI: 10.1097/00000658-200206000-00012
  18. Lammert F., Miquel J.F. Gallstone disease: from genes to evidence-based therapy. J Hepatol. 2008; 48 (Suppl 1): S124–35. DOI: 10.1016/j.jhep.2008.01.012
  19. Buch S., Schafmayer C., Völzke H. et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet. 2007; 39 (8): 995–9. DOI: 10.1038/ng2101
  20. Rebholz C., Krawczyk M., Lammert F. Genetics of gallstone disease. Eur J Clin Invest. 2018; 48 (7): e12935. DOI: 10.1111/eci.12935
  21. Biddinger S.B., Haas J.T., Yu B.B. et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med. 2008; 14 (7): 778–82. DOI: 10.1038/nm1785
  22. Lambert J.E., Ramos-Roman M.A., Browning J.D. et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014; 146 (3): 726–35. DOI: 10.1053/j.gastro.2013.11.049
  23. Tanaka N., Aoyama T., Kimura S. et al. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol Ther. 2017; 179: 142–57. DOI: 10.1016/j.pharmthera.2017.05.011
  24. Arab J.P., Karpen S.J., Dawson P.A. et al. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology. 2017; 65 (1): 350–62. DOI: 10.1002/hep.28709
  25. Yu D.D., Andrali S.S., Li H. et al. Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease. Bioorg Med Chem. 2016; 24 (18): 3986–93. DOI: 10.1016/j.bmc.2016.06.039
  26. Drapkina O.M., Fomicheva E.I. Membrane bile acid receptor TGR5 – a new target in the study of metabolic, inflammatory and neoplastic diseases. Ration Pharmacother Cardiol. 2016; 12 (3): 344–50. DOI: 10.20996/1819-6446-2016-12-3-344-350
  27. Liu C.M., Tung T.H., Tsai S.T. et al. Serum insulin, insulin resistance, beta-cell dysfunction, and gallstone disease among type 2 diabetics in Chinese population: a community-based study in Kinmen, Taiwan. World J Gastroenterol. 2005; 11 (45): 7159–64. DOI: 10.3748/wjg.v11.i45.7159
  28. Tsukanov V.V., Tonkih Ju.L., Vasjutin A.V. Lipidnyj sostav krovi i zhelchi i risk razvitija zhelchnokamennoj bolezni u bol'nyh saharnym diabetom 1 i 2 tipa. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2017; 27 (4): 36–40 [Tsukanov V.V., Tonkikh Yu.L., Vasyutin A.V. Blood and bile lipid composition and the risk of gallstones at diabetes mellitus of the 1st and 2nd type. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017; 27 (4): 36–40 (in Russ.)].
  29. Tsukanov V.V., Seliverstova E.V., Dogadin S.A. Pokazateli lipidnogo sostava syvorotki krovi i zhelchi pri zabolevanijah zhelchevyvodjaschih putej u bol'nyh saharnym diabetom. Ter arh. 2005; 77 (2): 15–8. [Tsukanov V.V., Seliverstova E.V., Dogadin S.A. Lipid composition of blood serum and bile in biliary diseases in patients with diabetes mellitus. Ter Arkh. 2005; 77 (2): 15–8 (in Russ.)].
  30. Tsukanov V.V., Tonkih Ju.L., Bronnikova E.P. i dr. Mehanizm normolipidemii u severnyh narodnostej. Klin med. 1999; 77 (2): 38–9. [Tsukanov V.V., Tonkikh Iu.L., Bronnikova E.P. et al. The mechanism of normolipidemia among the Northern area ethnic groups. Klin Med. 1999; 77 (2): 38–9 (in Russ.)].
  31. Tsukanov V.V. Kliniko-biohimicheskie osobennosti zabolevanij zhelchevyvodjaschih putej u naselenija Aziatskogo Severa. Avtoref. dis. ... d-ra med. nauk. Tomsk, 1996; 40 c. [Tsukanov V.V. Kliniko-biokhimicheskiye osobennosti zabolevaniy zhelchevyvodyashchikh putey u naseleniya Aziatskogo Severa. Avtoref. dis. ... d-ra med. nauk. Tomsk, 1996; 40 c. (in Russ.)].
  32. Tsukanov V.V., Nozdrachev K.G., Tonkih Ju.L. i dr. Metabolicheskie faktory zaschity korennogo naselenija Severa pri IBS i holelitiaze. Bjulleten' Sibirskogo otdelenija Rossijskoj akademii meditsinskih nauk. 2006; 26 (2): 100–4 [Tsukanov V.V., Nozdrachev K.G., Tonkikh Y.L. et al. Metabolic factors of protection from ischemic heart disease and cholelithiasis in native populations of the Nort. Byulleten’ Sibirskogo otdeleniya Rossiyskoy akademii meditsinskikh nauk. 2006; 26 (2): 100–4 (in Russ.)].
  33. Scherber P.R., Zúniga S.E., Glanemann M. et al. Gallstone disease – interdisciplinary treatment. Dtsch Med Wochenschr. 2020; 145 (5): 287–95. DOI: 10.1055/a-0944-8655
  34. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol. 2016; 65 (1): 146–81. DOI: 10.1016/j.jhep.2016.03.005
  35. Guarino M.P., Cocca S., Altomare A. et al. Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J Gastroenterol. 2013; 19 (31): 5029–34. DOI: 10.3748/wjg.v19.i31.5029
  36. National Institutes of Health Consensus Development Conference Statement on Gallstones and Laparoscopic Cholecystectomy [No authors listed]. Am J Surg. 1993; 165 (4): 390–8. DOI: 10.1016/s0002-9610(05)80929-8
  37. Beuers U., Boberg K.M., Chapman R.W. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009; 51 (2): 237–67. DOI: 10.1016/j.jhep.2009.04.009
  38. Portincasa P., Ciaula A.D., Bonfrate L. et al. Therapy of gallstone disease: What it was, what it is, what it will be. World J Gastrointest Pharmacol Ther. 2012; 3 (2): 7–20. DOI: 10.4292/wjgpt.v3.i2.7